Managed Account Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Managed Account Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-23,762	Closed	-$2.32M	–	3205
2015 Q1	$2.32M	Buy	+23,762	New	+$2.52M	﹤0.01%	1781
2014 Q4	–	Sell	-3,852	Closed	-$265K	–	2827
2014 Q3	$265K	Sell	3,852 -12,807	-77%	-$917K	﹤0.01%	2279
2014 Q2	$1.75M	Sell	16,659 -5,629	-25%	-$479K	﹤0.01%	1827
2014 Q1	$1.85M	Buy	22,288 +13,245	+146%	+$1.22M	﹤0.01%	1764
2013 Q4	$585K	Sell	9,043 -530	-6%	-$31.5K	﹤0.01%	2034
2013 Q3	$607K	Sell	9,573 -8,434	-47%	-$415K	﹤0.01%	1979
2013 Q2	$756K	Buy	+18,007	New	+$821K	﹤0.01%	1929

Managed Account Advisors's GEVA Position: Q2 2015 in Review

Managed Account Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 23,762 shares — an estimated $2.32M sold.

Managed Account Advisors first reported a position in GEVA in Q2 2013 and held it in 7 quarters. The position peaked at $2.32M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Managed Account Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Managed Account Advisors sold 23,762 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $2.32M.
Managed Account Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 7 quarters.
Managed Account Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.32M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.